glp-1 drug news today A wave of new #GLP1 options for type 2 #Diabetes and #Obesity was a major focus at #ADA2026. In the latest JAMA Medical podcast, Jennifer Abbasi interviews Rita Kalyani, MD GLP-1 Agonists Weight Loss Drugs

[113] According to Novo Nordisk, under the ChinaSwitzerland Free Trade Agreement, semaglutide is subject to regulatory data protection in China until April 2027, and their Swiss subsidiary holds those rights exclusively

Still, clinicians should remain alert

Also, patients with renal impairment should monitor kidney function when taking these medications

Most best GLP-1 program lists still treat a 28-year-old with 15 vanity pounds and a 52-year-old in perimenopause as the same customer

Recently, pharmacologic agonists of glucose-dependent insulinotropic polypeptide (GIP), an incretin synthesized in the K-cells of the duodenum and jejunum, have also become available